Zura Bio (NASDAQ:ZURA) Earns “Buy” Rating from Guggenheim

Zura Bio (NASDAQ:ZURA)‘s stock had its “buy” rating restated by analysts at Guggenheim in a research note issued on Wednesday,Benzinga reports. They presently have a $15.00 target price on the stock.

A number of other analysts also recently issued reports on the company. Chardan Capital cut their price objective on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Finally, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $15.00.

Zura Bio Price Performance

Shares of ZURA stock opened at $1.36 on Wednesday. The company’s 50-day moving average price is $1.47 and its 200-day moving average price is $2.75. Zura Bio has a twelve month low of $1.07 and a twelve month high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.09. The firm had revenue of $0.00 million for the quarter. Equities research analysts forecast that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. American Century Companies Inc. purchased a new position in Zura Bio in the 4th quarter valued at approximately $27,000. Prudential Financial Inc. purchased a new position in Zura Bio in the fourth quarter valued at $28,000. Two Sigma Advisers LP purchased a new position in Zura Bio in the fourth quarter valued at $32,000. ProShare Advisors LLC acquired a new position in Zura Bio during the 4th quarter worth $35,000. Finally, XTX Topco Ltd purchased a new stake in Zura Bio during the 4th quarter worth about $44,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.